[HTML][HTML] Covid-19 vaccines—immunity, variants, boosters
DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
[HTML][HTML] COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
[HTML][HTML] A bivalent omicron-containing booster vaccine against Covid-19
S Chalkias, C Harper, K Vrbicky… - … England Journal of …, 2022 - Mass Medical Soc
Background The safety and immunogenicity of the bivalent omicron-containing mRNA-
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
[HTML][HTML] A Covid-19 milestone attained—a correlate of protection for vaccines
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
[HTML][HTML] The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
M Hoffmann, N Krüger, S Schulz, A Cossmann… - Cell, 2022 - cell.com
The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become
globally dominant. Further, the high number of mutations in the viral spike protein raised …
globally dominant. Further, the high number of mutations in the viral spike protein raised …
[HTML][HTML] Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
CH GeurtsvanKessel, D Geers, KS Schmitz… - Science …, 2022 - science.org
The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …
SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …
assessed in serum samples obtained from persons who had received an mRNA-1273 …
Population immunity and Covid-19 severity with Omicron variant in South Africa
Abstract Background The B. 1.1. 529 (omicron) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …
[HTML][HTML] Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …
individuals,–. Despite the reduced protection from infection, individuals who received three …